ATE426805T1 - Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind - Google Patents

Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind

Info

Publication number
ATE426805T1
ATE426805T1 AT01972994T AT01972994T ATE426805T1 AT E426805 T1 ATE426805 T1 AT E426805T1 AT 01972994 T AT01972994 T AT 01972994T AT 01972994 T AT01972994 T AT 01972994T AT E426805 T1 ATE426805 T1 AT E426805T1
Authority
AT
Austria
Prior art keywords
methods
low molecular
products associated
molecular heparin
products
Prior art date
Application number
AT01972994T
Other languages
English (en)
Inventor
Mallikarjum Sundaram
Ganesh Venkataraman
Zachary Shriver
Dongfang Liu
Yi Qi
Ram Sasisekharan
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE426805T1 publication Critical patent/ATE426805T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
AT01972994T 2000-09-12 2001-09-12 Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind ATE426805T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23199400P 2000-09-12 2000-09-12

Publications (1)

Publication Number Publication Date
ATE426805T1 true ATE426805T1 (de) 2009-04-15

Family

ID=22871450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972994T ATE426805T1 (de) 2000-09-12 2001-09-12 Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind

Country Status (12)

Country Link
US (6) US7083937B2 (de)
EP (2) EP2085780B1 (de)
JP (2) JP4911865B2 (de)
AT (1) ATE426805T1 (de)
AU (1) AU2001292618A1 (de)
CA (1) CA2422059C (de)
CY (1) CY1110323T1 (de)
DE (1) DE60138115D1 (de)
DK (1) DK1319183T3 (de)
ES (2) ES2324701T3 (de)
PT (1) PT1319183E (de)
WO (1) WO2002023190A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1109919A2 (de) * 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Von heparinase i und ii abgeleitete heparinasen
JP4824170B2 (ja) * 1999-04-23 2011-11-30 マサチューセッツ インスティテュート オブ テクノロジー ポリマーを表記するためのシステムおよび方法
CA2402160C (en) * 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
DE60138115D1 (de) * 2000-09-12 2009-05-07 Massachusetts Inst Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
AU2002224408B2 (en) * 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2003033512A2 (en) * 2001-10-16 2003-04-24 Procognia, Ltd. Method of preparing purified biologically active oligosaccharide libraries
EP2402753A1 (de) * 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analyse von sulfatierten Polysacchariden
EP1551852A4 (de) * 2002-04-25 2007-03-21 Momenta Pharmaceuticals Inc Verfahren und produkte zur verabreichung an die schleimhaut
ES2421134T3 (es) * 2002-05-03 2013-08-29 Massachusetts Institute Of Technology delta 4,5 Glicuronidasa y usos de la misma
AU2003302219B8 (en) * 2002-05-20 2009-03-26 Instituto Di Recherche Chimiche E Biochimiche G. Ronzoni Novel method for sequence determination using NMR
CA2493509C (en) * 2002-06-03 2010-03-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
JP4606712B2 (ja) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
DE10315581B4 (de) 2003-04-05 2007-06-28 Agilent Technologies, Inc. (n.d.Ges.d.Staates Delaware), Palo Alto Verfahren zur Qualitätsbestimmung von RNA-Proben
CN1886427B (zh) 2003-11-28 2012-05-23 伊士曼化工公司 纤维素共聚体和氧化方法
EP1737954A2 (de) 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Rekombinante chondroitinase abc i und verwendungen davon
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) * 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060002594A1 (en) * 2004-06-09 2006-01-05 Clarke Allan J Method for producing a pharmaceutical product
TWI356036B (en) * 2004-06-09 2012-01-11 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
US8101244B2 (en) * 2004-06-09 2012-01-24 Smithkline Beecham Corporation Apparatus and method for producing or processing a product or sample
EP1768687A2 (de) 2004-06-29 2007-04-04 Massachusetts Institute Of Technology Verfahren und zusammensetzungen in zusammenhang mit der modulation intrazellulärer verbindungen
WO2006083328A2 (en) * 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
DE102005038418A1 (de) * 2005-08-12 2007-02-15 Dade Behring Marburg Gmbh Faktor Xa-basierter Heparinassay unter Verwendung einer Heparin-modifizierenden Komponente
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
WO2007120478A2 (en) * 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
CA2652205A1 (en) 2006-05-25 2007-12-06 Mallik Sundaram Low molecular weight heparin composition and uses thereof
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
CA2674493C (en) * 2007-01-05 2017-05-09 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
EP2509607B1 (de) * 2009-12-09 2017-09-06 Agency For Science, Technology And Research Glycosaminoglycanmischungen
US8435795B2 (en) * 2010-01-19 2013-05-07 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
JP5645493B2 (ja) * 2010-06-15 2014-12-24 川崎重工業株式会社 多糖類検査装置および多糖類検査方法
WO2012016216A2 (en) 2010-07-29 2012-02-02 Shire Human Genetic Therapies Assays for detection of glycosaminoglycans
WO2012036152A1 (ja) * 2010-09-14 2012-03-22 国立大学法人 宮崎大学 高純度ヘパリンおよびその製造方法
AU2015203727B2 (en) * 2010-09-14 2016-05-26 Fuso Pharmaceutical Industries, Ltd. High Purity Heparin and Production Method Therefor
WO2012100733A1 (zh) * 2011-01-28 2012-08-02 杭州九源基因工程有限公司 一种基于毛细管电泳的依诺肝素钠精细结构测定方法
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN104144950B (zh) * 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
WO2013116677A2 (en) * 2012-02-01 2013-08-08 Shire Human Genetic Therapies, Inc. Assays for detection of glycosaminoglycans
ES2445494B1 (es) * 2012-08-02 2015-03-06 Rovi Lab Farmaceut Sa Procedimiento de obtención de heparinas de bajo y muy bajo peso molecular
EP3997238A1 (de) 2019-07-09 2022-05-18 Optimvia, LLC Verfahren zur synthese von antikoagulierenden polysacchariden
CN111019014A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种那曲肝素钙的制备工艺
EP4182452A1 (de) 2020-07-14 2023-05-24 Optimvia, LLC Verfahren zur synthese von nicht-antikoagulierendem heparansulfat
CN114264741B (zh) * 2021-12-15 2022-08-19 山东大学 一种鉴别猪来源肝素是否掺反刍类动物肝素的方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1390633A (en) * 1921-06-17 1921-09-13 Edgar A Milhaupt Bumper-bracket
US4281108A (en) 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
US4341869A (en) 1980-08-25 1982-07-27 Massachusetts Institute Of Technology Process for producing heparinase
US4443545A (en) 1980-08-25 1984-04-17 Massachusetts Institute Of Technology Process for producing heparinase
US4373023A (en) 1980-10-14 1983-02-08 Massachusetts Institute Of Technology Process for neutralizing heparin
US4396762A (en) 1981-08-24 1983-08-02 Massachusetts Institute Of Technology Heparinase derived anticoagulants
US4551296A (en) 1982-03-19 1985-11-05 Allied Corporation Producing high tenacity, high modulus crystalline article such as fiber or film
FR2554348B1 (fr) 1983-11-04 1987-01-23 Tissier Gerard Complexes hepariniques marques au moyen de radio-elements de vie courte emetteurs de radiations non ionisantes, leur procede d'obtention, les produits intermediaires et application de ces complexes
US4757056A (en) 1984-03-05 1988-07-12 Hepar Industries, Inc. Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions
US4679555A (en) 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
US5262403A (en) 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
DK196986D0 (da) 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
US5106734A (en) 1986-04-30 1992-04-21 Novo Nordisk A/S Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin
US4942156A (en) 1986-08-20 1990-07-17 Hepar Industries, Inc. Low molecular weight heparin derivatives having improved anti-Xa specificity
US4745105A (en) 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US4830013A (en) 1987-01-30 1989-05-16 Minnesota Mining And Manufacturing Co. Intravascular blood parameter measurement system
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
US5169772A (en) 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
IT1234508B (it) 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
GB8826448D0 (en) 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
US5776434A (en) 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
CA1340966C (en) 1989-05-19 2000-04-18 Thomas R. Covey Method of protein analysis
IT1237518B (it) 1989-11-24 1993-06-08 Renato Conti Eparine supersolfatate
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5152784A (en) 1989-12-14 1992-10-06 Regents Of The University Of Minnesota Prosthetic devices coated with a polypeptide with type IV collagen activity
US5284558A (en) 1990-07-27 1994-02-08 University Of Iowa Research Foundation Electrophoresis-based sequencing of oligosaccharides
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
JP3110064B2 (ja) 1991-03-06 2000-11-20 生化学工業株式会社 新規ヘパリチナーゼ、その製造法及びその生産菌
US5262325A (en) 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
WO1992019249A1 (en) 1991-05-02 1992-11-12 Yeda Research And Development Co. Ltd. Compositions for the prevention and/or treatment of pathological processes
WO1993005167A1 (en) 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
EP0641438A1 (de) 1991-11-21 1995-03-08 Glyko, Inc. Fluorophor-unterstirte kontrolle medikamentoser therapien
GB9202019D0 (en) 1992-01-30 1992-03-18 Imperial College Methods and apparatus for assay of sulphated polysaccharides
IT1254216B (it) 1992-02-25 1995-09-14 Opocrin Spa Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
US5453171A (en) 1992-03-10 1995-09-26 The Board Of Regents Of The University Of Michigan Heparin-selective polymeric membrane electrode
US5856928A (en) 1992-03-13 1999-01-05 Yan; Johnson F. Gene and protein representation, characterization and interpretation process
GB9206291D0 (en) 1992-03-23 1992-05-06 Cancer Res Campaign Tech Oligosaccharides having growth factor binding affinity
WO1993019734A1 (en) 1992-04-02 1993-10-14 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
GB9306255D0 (en) 1993-03-25 1993-05-19 Cancer Res Campaign Tech Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity
FR2704861B1 (fr) 1993-05-07 1995-07-28 Sanofi Elf Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant.
US7005510B1 (en) * 1993-06-23 2006-02-28 Beckman Instruments, Inc. Recombinant DNase B derived from Streptococcus pyogenes
WO1995013830A1 (en) 1993-11-17 1995-05-26 Massachusetts Institute Of Technology Method for inhibiting angiogenesis using heparinase
US6013628A (en) 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US6376196B1 (en) * 1996-05-10 2002-04-23 The Regents Of The University Of California Recombinant neospora antigens and their uses
US5607859A (en) 1994-03-28 1997-03-04 Massachusetts Institute Of Technology Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
CA2189038A1 (en) 1994-05-06 1995-11-09 Kevin R. Holme O-desulfated heparin derivatives, methods of making and uses thereof
US5681733A (en) 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
US5619421A (en) 1994-06-17 1997-04-08 Massachusetts Institute Of Technology Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723847A1 (fr) 1994-08-29 1996-03-01 Debiopharm Sa Compositions antithrombotiques et non hemorragiques a base d'heparine, procede pour leur preparation et applications therapeutiques.
US5687090A (en) 1994-09-01 1997-11-11 Aspen Technology, Inc. Polymer component characterization method and process simulation apparatus
DE69520044T2 (de) 1994-10-12 2001-06-13 Focal Inc Zielgerichte verabreichung mittels biologisch abbaubarer polymere
US5569366A (en) * 1995-01-27 1996-10-29 Beckman Instruments, Inc. Fluorescent labelled carbohydrates and their analysis
US5618917A (en) 1995-02-15 1997-04-08 Arch Development Corporation Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
US5763427A (en) 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
JP3318578B2 (ja) 1995-05-26 2002-08-26 サーモディックス，インコーポレイティド 内皮化を促進するための方法及び移植用製品
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US5690910A (en) 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5752019A (en) 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
WO1997040819A1 (en) 1996-04-29 1997-11-06 Dura Pharmaceuticals, Inc. Methods of dry powder inhalation
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
WO1998004902A1 (en) 1996-07-26 1998-02-05 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Sensor for detecting heparin and other analytes
DE69728410T2 (de) * 1996-08-08 2005-05-04 William Marsh Rice University, Houston Makroskopisch manipulierbare, aus nanoröhrenanordnungen hergestellte vorrichtungen
US5759767A (en) 1996-10-11 1998-06-02 Joseph R. Lakowicz Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6190875B1 (en) * 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
US6268146B1 (en) 1998-03-13 2001-07-31 Promega Corporation Analytical methods and materials for nucleic acid detection
EP1109919A2 (de) 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Von heparinase i und ii abgeleitete heparinasen
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US6291439B1 (en) * 1998-09-02 2001-09-18 Biomarin Pharmaceuticals Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
JP4824170B2 (ja) * 1999-04-23 2011-11-30 マサチューセッツ インスティテュート オブ テクノロジー ポリマーを表記するためのシステムおよび方法
CA2402160C (en) 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
IL151170A0 (en) * 2000-03-14 2003-04-10 Es Cell Int Pte Ltd Embryonic stem cells and neural progenitor cells derived therefrom
US6373194B1 (en) * 2000-06-01 2002-04-16 Raytheon Company Optical magnetron for high efficiency production of optical radiation
DE60138115D1 (de) 2000-09-12 2009-05-07 Massachusetts Inst Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
AU2002224408B2 (en) 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US6777244B2 (en) * 2000-12-06 2004-08-17 Hrl Laboratories, Llc Compact sensor using microcavity structures
US20020071457A1 (en) * 2000-12-08 2002-06-13 Hogan Josh N. Pulsed non-linear resonant cavity
JP2005503120A (ja) 2001-03-27 2005-02-03 マサチューセッツ　インスティテュート　オブ　テクノロジー Ｆｇｆダイマー化に関する方法及び生成物
US6788847B2 (en) * 2001-04-05 2004-09-07 Luxtera, Inc. Photonic input/output port
US7248297B2 (en) * 2001-11-30 2007-07-24 The Board Of Trustees Of The Leland Stanford Junior University Integrated color pixel (ICP)
EP1471828A1 (de) * 2002-01-18 2004-11-03 California Institute Of Technology Verfahren und gerät für die nanomagnetische manipulation und messung
ES2421134T3 (es) 2002-05-03 2013-08-29 Massachusetts Institute Of Technology delta 4,5 Glicuronidasa y usos de la misma
AU2003302219B8 (en) 2002-05-20 2009-03-26 Instituto Di Recherche Chimiche E Biochimiche G. Ronzoni Novel method for sequence determination using NMR
CA2493509C (en) 2002-06-03 2010-03-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
US6887773B2 (en) * 2002-06-19 2005-05-03 Luxtera, Inc. Methods of incorporating germanium within CMOS process
US8228959B2 (en) * 2002-09-27 2012-07-24 The Trustees Of Dartmouth College Free electron laser, and associated components and methods
US6922118B2 (en) * 2002-11-01 2005-07-26 Hrl Laboratories, Llc Micro electrical mechanical system (MEMS) tuning using focused ion beams
JP4606712B2 (ja) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
US7141800B2 (en) * 2003-07-11 2006-11-28 Charles E. Bryson, III Non-dispersive charged particle energy analyzer
US20050186679A1 (en) * 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
US7851223B2 (en) 2004-02-27 2010-12-14 Roar Holding Llc Method to detect emphysema
EP1737954A2 (de) 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Rekombinante chondroitinase abc i und verwendungen davon
EP1582531A1 (de) * 2004-03-24 2005-10-05 Aventis Pharma S.A. Verfahren zur Oxydierung nicht-fraktionierten Heparins und die Detektion der Anwesenheit oder Abwesenheit von Glykoserin in Heparin und in von Heparin abgeleiteten Produkten
US20060057638A1 (en) 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
EP1768687A2 (de) 2004-06-29 2007-04-04 Massachusetts Institute Of Technology Verfahren und zusammensetzungen in zusammenhang mit der modulation intrazellulärer verbindungen
US7586097B2 (en) * 2006-01-05 2009-09-08 Virgin Islands Microsystems, Inc. Switching micro-resonant structures using at least one director
WO2006083328A2 (en) 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
US20060187794A1 (en) * 2004-10-14 2006-08-24 Tim Harvey Uses of wave guided miniature holographic system
WO2006076627A2 (en) 2005-01-12 2006-07-20 Massachusetts Institute Of Technology Methods and compositions related to modulating the extracellular stem cell environment
US20090155875A1 (en) 2005-02-16 2009-06-18 Massachusetts Institute Of Technology Methods to Enhance Carbon Monoxide Dehydrogenase Activity and Uses Thereof
US20090105463A1 (en) * 2005-03-29 2009-04-23 Massachusetts Institute Of Technology Compositions of and Methods of Using Oversulfated Glycosaminoglycans
WO2006105315A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions and methods for regulating inflammatory responses
US7619373B2 (en) * 2006-01-05 2009-11-17 Virgin Islands Microsystems, Inc. Selectable frequency light emitter
WO2007120478A2 (en) 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
CA2674493C (en) 2007-01-05 2017-05-09 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum

Also Published As

Publication number Publication date
US8512969B2 (en) 2013-08-20
EP2085780A3 (de) 2011-08-17
EP2085780B1 (de) 2017-06-21
US20070161073A1 (en) 2007-07-12
WO2002023190A8 (en) 2011-10-27
US7399604B2 (en) 2008-07-15
ES2324701T3 (es) 2009-08-13
EP1319183B1 (de) 2009-03-25
WO2002023190A3 (en) 2003-03-13
JP4911865B2 (ja) 2012-04-04
US8173384B2 (en) 2012-05-08
WO2002023190A2 (en) 2002-03-21
AU2001292618A1 (en) 2002-03-26
CA2422059A1 (en) 2002-03-21
US20060024664A1 (en) 2006-02-02
US7687479B2 (en) 2010-03-30
CA2422059C (en) 2012-05-15
US20130017565A1 (en) 2013-01-17
EP1319183A2 (de) 2003-06-18
US7083937B2 (en) 2006-08-01
US20070065921A1 (en) 2007-03-22
JP2011169913A (ja) 2011-09-01
CY1110323T1 (el) 2014-02-12
DE60138115D1 (de) 2009-05-07
US20100062468A1 (en) 2010-03-11
US7585642B2 (en) 2009-09-08
DK1319183T3 (da) 2009-05-18
EP2085780A2 (de) 2009-08-05
PT1319183E (pt) 2009-06-29
ES2640975T3 (es) 2017-11-07
JP2004509339A (ja) 2004-03-25
US20020169143A1 (en) 2002-11-14
JP5186019B2 (ja) 2013-04-17

Similar Documents

Publication Publication Date Title
ATE426805T1 (de) Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
FR2841900B1 (fr) Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
DE69716135T2 (de) In 6-position durch thio substituierte paclitaxele
ECSP034442A (es) Mezclas de polisacaridos derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienen
ITCO990031A0 (it) Metodo ed apparecchiatura per la produzione di articoli tridimensional i di maglieria e calzetteria e prodotti risultanti.
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
ITMI20000665A0 (it) Glicosaminoglicani derivati dal polisaccaride k5 aventi elevata attivita' anticoagulante ed antitrombotica e processo per la loro preparazio
EA200000531A1 (ru) Применение кетолидов для профилактики тромботических артериальных осложнений, связанных с атеросклерозом
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
SE9803107D0 (sv) Novel Compunds
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
IT1302971B1 (it) Procedimento di produzione per prosciutti, e mezzi relativi alprocedimento
TH52542S (th) "แท่นยึดลูกล้อสำหรับรางประตูหน้าต่าง"
TH36511EX (th) ตู้เสื้อผ้า 2 ประตู
TH36509EX (th) ตู้เสื้อผ้า 2 ประตู
FR2748030B1 (fr) Nouveaux produits colloidaux, leur preparation et leurs utilisations
DK1343826T3 (da) Polysaccharid med immunstimulerende aktivitet
TH54744EX (th) ตู้วางไวน์
TH54345EX (th) ถาด
TH37915EX (th) ชิ้นส่วนกรอบหน้าต่าง
DE29717513U1 (de) Stecksystem für die Herstellung von Möbeln u.dgl.
SE9803277D0 (sv) Novel compounds
TH46231EX (th) กระจก
ECSP003412A (es) Derivados de 3- amino -3-arilpropan - 1 - ol, su preparacion y su uso

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1319183

Country of ref document: EP